AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

Delisting risk

RNAZ · NASDAQ · Biotechnology

TransCode Therapeutics (RNAZ)

Develops RNA-delivery and immuno-oncology candidates for metastatic and other cancers.

$2.01

At close−0.05 (−2.43%)

Watchlist

Something off on this page? Send us feedback.

Breakdown13F · 13D/G · Form 4

	Institutions7 holders · as of Mar 31, 2026	0.18%	30.9K shares
	Otherremainder	99.82%	16.90M shares

16.93M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing

Two share counts disagree (16.93M in the company's Sep 3, 2026 report, 1.06M elsewhere); stakes use the report.

Top shareholders13F · 13D/G · Form 4

Holder	Stake	Shares	Evidence
Geode Capital Management, LLCInstitution	0.08%	12,740	13Fas of Mar 31, 2026
UBS Group AGInstitution	0.05%	8,295	13Fas of Mar 31, 2026
Vanguard Capital Management LLCInstitution	0.04%	6,545	13Fas of Mar 31, 2026
Vanguard Fiduciary Trust CoInstitution	0.02%	2,982	13Fas of Mar 31, 2026
Tower Research Capital LLC (TRC)Institution	0.00%	228	13Fas of Mar 31, 2026
Wells Fargo & Company/MNInstitution	0.00%	55	13Fas of Mar 31, 2026
Sbi Securities Co., Ltd.Institution	0.00%	12	13Fas of Mar 31, 2026
AIGH Capital Management, LLCStrategic	—9.90% of class, as filed	—	13Gfiled Jul 21, 2021 ↗
CK Life Sciences Int'l., (Holdings) Inc.Strategic	—83.90% of class, as filed	—	13Dfiled Aug 3, 2026 ↗
Daniel Eduardo KatzmanInsider	—5.16% of class, as filed	—	13Gfiled Jul 28, 2026 ↗
Elena Rosa BraciInsider	—6.17% of class, as filed	—	13Gfiled Jul 28, 2026 ↗
Lind Global Fund II LPInstitution	—9.90% of class, as filed	—	13Gfiled Dec 7, 2023 ↗
Management LLCStrategic	—9.90% of class, as filed	—	13Gfiled Jul 26, 2024 ↗
Sabby Management, LLCStrategic	—9.90% of class, as filed	—	13Gfiled Jan 3, 2025 ↗
Thomas Joseph TracyInsider	—5.00% of class, as filed	—	13Dfiled Mar 20, 2025 ↗
Unleash Immuno Oncolytics, Inc.Strategic	—9.94% of class, as filed	—	13Gfiled Jul 28, 2026 ↗
YA II PN, Ltd.Strategic	—9.90% of class, as filed	—	13Gfiled Apr 20, 2026 ↗
Defj, LLC¹Strategic10 percent owner	83.48%	14.13M	Form 4filed Aug 5, 2026 ↗
Robert Michael Dudley²Insiderdirector, officer: Chief Executive Officer	0.00%	5	Form 4filed Oct 2, 2023 ↗
Anna Moore³Insider10 percent owner	0.00%	2	Form 4filed Jul 8, 2021 ↗
Thomas A. Fitzgerald²Insiderdirector, officer: Chief Financial Officer	0.00%	2	Form 4filed Oct 2, 2023 ↗
Philippe Calais³Insiderdirector	0.00%	0	Form 4filed Jul 8, 2021 ↗
Zdravka Medarova^3,4Insider10 percent owner	0.00%	0	Form 4filed Jul 8, 2021 ↗

This 14.13M-share position rests on a single filing; nothing else on file confirms it.
Last filed Oct 2, 2023; leaving the company requires no filing. Not in the bar.
Last filed Jul 8, 2021; leaving the company requires no filing. Not in the bar.
Zdravka Medarova reports a block also reported by Anna Moore; it is counted once, under Anna Moore.

13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report

Institutions13F, as of Mar 31, 2026

7 holders · 30.9K shares · 4 new positions · 6 increased · 1 reduced · 2 closed

Holder	Shares	% outstanding	Chg q/q	Filed
Geode Capital Management, LLC	12.7K	0.08%	+12.7Knew	May 15, 2026
UBS Group AG	8.3K	0.05%	+5.3K	May 5, 2026
Vanguard Capital Management LLC	6.5K	0.04%	+6.5Knew	May 15, 2026
Vanguard Fiduciary Trust Co	3.0K	0.02%	+3.0Knew	May 8, 2026
Tower Research Capital LLC (TRC)	228	0.00%	−659	May 15, 2026
Wells Fargo & Company/MN	55	0.00%	+55new	Jul 8, 2026
Sbi Securities Co., Ltd.	12	0.00%	+2	Apr 28, 2026

Ownership statements13D/G · 5% or more, as filed

Holder	% of class	Shares	Form	Filed
CK Life Sciences Int'l., (Holdings) Inc.incl. Defj, LLC	83.90%		13D	Aug 3, 2026 ↗
Unleash Immuno Oncolytics, Inc.	9.94%	300.0K	13G	Jul 28, 2026 ↗
YA II PN, Ltd.	9.90%	101.8K	13G	Apr 20, 2026 ↗
Sabby Management, LLC	9.90%		13G	Jan 3, 2025 ↗
Elena Rosa Braci	6.17%	186.2K	13G	Jul 28, 2026 ↗
Daniel Eduardo Katzman	5.16%	155.6K	13G	Jul 28, 2026 ↗
Thomas Joseph Tracy	5.00%		13D	Mar 20, 2025 ↗

TransCode Therapeutics (RNAZ)

Breakdown13F · 13D/G · Form 4

Top shareholders13F · 13D/G · Form 4

Institutions13F, as of Mar 31, 2026

Ownership statements13D/G · 5% or more, as filed

Insider tradesForm 4

Latest trades

CongressHouse and Senate disclosures